Loading
Stingray Therapeutics
Stingray Therapeutics is a Houston company developing vizenpistat, a tablet designed to switch back on an early-warning part of the immune system that many tumours turn off. It is being tested with two immunotherapy antibodies in bowel cancer that is microsatellite stable.
Also called: Stingray Therapeutics, Inc.
Overview
Stingray Therapeutics develops vizenpistat (SR-8541A), an oral inhibitor of ENPP1, the enzyme that breaks down 2'3'-cGAMP before it can activate STING; the company describes blocking ENPP1 as a way to restore cGAS-STING innate immune signalling. Its website lists a phase 1 single-agent dose-escalation study in advanced solid tumours (NCT06063681) and a phase 1b/2 study with botensilimab and balstilimab in metastatic microsatellite stable colorectal cancer (NCT06589440), funded by a CPRIT grant and an NCI SBIR award. In fiscal year 2026 NCI awarded it USD 1,460,952 under SBIR award 5R44CA278144-04 for that colorectal programme.
Headquarters
Houston, TX, US
Scorecard
All companies#742of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 5R44CA278144-04: A Phase 1-2 clinical program for the treatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1Phase 2Oral small-molecule ENPP1 inhibitor
Vizenpistat is an experimental tablet from Stingray Therapeutics that aims to restore an early immune alarm many tumours switch off. It is in early trials, including one with two immunotherapy antibodies in bowel cancer.
Notes
- Read on stingraytx.com, NIH RePORTER and ClinicalTrials.gov on 4 November 2026. The company's ranking and safety claims are its own. No ENPP1 target record exists in the corpus.
Connected
4Similar pages
cancers
fronts
drugs
Phase 2Oral small-molecule ENPP1 inhibitor
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
nih.gov · 1
stingraytx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/